NCT01069471View on ClinicalTrials.gov

Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Shigellosis
Interventions
BIOLOGICAL

Shigella vaccine

Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.

Trial Locations (1)

Unknown

Institute of Social and Preventive Medicine, Zurich

Sponsors

Lead Sponsor

GlycoVaxyn AG
All Listed Sponsors
lead

GlycoVaxyn AG

INDUSTRY